Document Detail


Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs.
MedLine Citation:
PMID:  20935081     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sphingosine-1-phosphate and its receptors have emerged as important modulators of the immune response. The sphingosine-1-phosphate prodrug 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol (FTY720) can alleviate experimental allergic airway inflammation. Nevertheless, the role of individual sphingosine-1-phosphate receptors in the regulation of allergic airway inflammation remains undefined. Using a newly characterized potent and selective sphingosine-1-phosphate receptor 1 (S1P₁) agonist with physical properties allowing airway delivery, we studied the contribution of S1P₁ signaling to eosinophilic airway inflammation induced in ovalbumin-immunized mice by airway challenges with ovalbumin. Airway delivery of receptor-nonselective sphingosine-1-phosphate prodrug significantly inhibits the sequential accumulation of antigen-presenting dendritic cells and CD4+ T cells in draining lymph nodes. This in turn suppressed by >80% the accumulation of CD4+ T cells and eosinophils in the airways. Systemic delivery of sphingosine-1-phosphate prodrug or of an S1P)₁-specific agonist at doses sufficient to induce lymphopenia did not inhibit eosinophil accumulation in the airways. In contrast, local airway delivery of S1P₁-specific agonist inhibited airways release of endogenous CCL5 and CCL17 chemokines, and significantly suppressed accumulation of activated T cells and eosinophils in the lungs. Specific S1P₁ agonism in lungs contributes significantly to anti-inflammatory activities of sphingosine-1-phosphate therapeutics by suppressing chemokine release in the airways, and may be of clinical relevance.
Authors:
David Marsolais; Saiko Yagi; Tomoyuki Kago; Nora Leaf; Hugh Rosen
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-10-08
Journal Detail:
Title:  Molecular pharmacology     Volume:  79     ISSN:  1521-0111     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-15     Completed Date:  2011-01-13     Revised Date:  2012-01-02    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  61-8     Citation Subset:  IM    
Affiliation:
Department of Chemical Physiology, The Scripps Research Institute, La Jolla, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allergens / toxicity*
Animals
Chemokines / metabolism*,  physiology
Lung / drug effects,  physiology
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Ovalbumin / toxicity
Pneumonia / immunology*,  metabolism,  pathology*
Prodrugs / pharmacology,  therapeutic use
Receptors, Lysophospholipid / agonists,  physiology
Receptors, Lysosphingolipid / agonists*,  physiology*
Thiophenes / pharmacology,  therapeutic use
beta-Alanine / analogs & derivatives,  pharmacology,  therapeutic use
Grant Support
ID/Acronym/Agency:
AI05509/AI/NIAID NIH HHS; AI074564/AI/NIAID NIH HHS; MH074404/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/AUY 954; 0/Allergens; 0/Chemokines; 0/Prodrugs; 0/Receptors, Lysophospholipid; 0/Receptors, Lysosphingolipid; 0/Thiophenes; 107-95-9/beta-Alanine; 9006-59-1/Ovalbumin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carotid artery hemodynamics: observing patient-specific changes with amlodipine and lisinopril by us...
Next Document:  Aminoglycosides inhibit KCNQ4 channels in cochlear outer hair cells via depletion of phosphatidylino...